Product Information

LOTEMAX SM 0.38% OPHTH GEL is a brand product labeled by Bausch & Lomb Incorporated, priced at $49.4864 per GM under NDC 24208050707. Its NADAC has been published 371 times since Jul 17, 2019.

FDA first approved this application on Feb 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the loteprednol etabonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

LOTEMAX SM 0.38% OPHTH GEL

loteprednol etabonate
$49.4864per GM
High Outlier

Strength

3.8 mg/g

NDC

24208050707

Classification

Brand

Dosage Form

GEL

Route

OPHTHALMIC

Effective Date

8/19/2026

Active Ingredients

LOTEPREDNOL ETABONATE

Approval Type

New Drug (NDA)

FDA Application

NDA208219

FDA Approved

2/22/2019

TE Code

AB

On Market Since

2/25/2019

Pharmacological Classes

Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for LOTEMAX SM 0.38% OPHTH GEL has been published 371 times since Jul 17, 2019, and over the history we have for it it has risen 35.2%. The table below summarizes its recorded NADAC range and movement.

Current price$49.4864 per GM
All-time high$49.6720 (May 14, 2025)
All-time low$36.5996 (Jul 17, 2019)
52-week high$49.5562
52-week low$49.4681
Median price$46.0569
Average price$44.5613
Largest weekly change+6.0% (Jan 10, 2024)
Weeks tracked371
Tracking sinceJul 17, 2019

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

+0.0%

1Y

-0.1%

3Y

+7.0%

5Y

+20.3%

All

+35.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the loteprednol etabonate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of LOTEMAX SM 0.38% OPHTH GEL?

The current National Average Drug Acquisition Cost (NADAC) for LOTEMAX SM 0.38% OPHTH GEL, manufactured by Bausch & Lomb Incorporated, is $49.4864 per GM (NDC 24208050707), effective Aug 19, 2026.

How has the price of LOTEMAX SM 0.38% OPHTH GEL changed over time?

Over the history we have for it, the NADAC for LOTEMAX SM 0.38% OPHTH GEL has risen 35.2%. It has been tracked across 371 weekly CMS publications since Jul 17, 2019.

What are the highest and lowest recorded NADAC prices for LOTEMAX SM 0.38% OPHTH GEL?

Since Jul 17, 2019, the NADAC for LOTEMAX SM 0.38% OPHTH GEL has ranged from a low of $36.5996 (Jul 17, 2019) to a high of $49.6720 (May 14, 2025), with a median of $46.0569 per GM.

Are there cheaper alternatives to LOTEMAX SM 0.38% OPHTH GEL?

No other NADAC-published product currently shares the active ingredient and strength of LOTEMAX SM 0.38% OPHTH GEL in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures LOTEMAX SM 0.38% OPHTH GEL?

LOTEMAX SM 0.38% OPHTH GEL (NDC 24208050707) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.